Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Declines By 85.6%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 9,220 shares, a decline of 85.6% from the March 31st total of 63,863 shares. Based on an average trading volume of 66,766 shares, the short-interest ratio is presently 0.1 days. Currently, 1.0% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, China SXT Pharmaceuticals currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of China SXT Pharmaceuticals in the 4th quarter valued at $36,000. Virtu Financial LLC grew its holdings in shares of China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after buying an additional 15,013 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of China SXT Pharmaceuticals in the 3rd quarter valued at $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Price Performance

Shares of SXTC stock traded down $0.02 on Friday, hitting $2.10. The stock had a trading volume of 21,083 shares, compared to its average volume of 102,024. China SXT Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $1,046.98. The company has a fifty day moving average price of $1.99 and a two-hundred day moving average price of $105.62.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.